Eric Singhi/X
Jan 9, 2025, 04:05
Eric K. Singhi: Does MARIPOSA study update simplify first-line treatment decisions?
Eric K. Singhi, Assistant Professor in the Department of General Oncology at The University of Texas MD Anderson Cancer Center, posted on X:
“MARIPOSA study update: Combination therapy shows over ONE-YEAR mOS improvement compared to osimertinib alone.
Key data to discuss with patients in clinic—but does this simplify first-line treatment decisions?”
Dr. Eric K. Singhi is a thoracic and head and neck medical oncologist, currently serving as an Assistant Professor in the Department of General Oncology within the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 9, 2025, 18:29
Feb 9, 2025, 18:21
Feb 9, 2025, 18:09
Feb 9, 2025, 18:06
Feb 9, 2025, 17:54
Feb 9, 2025, 17:24